MICB and neoplasm: The class 1 HDAC inhibitor, entinostat, has been shown to upregulate MHC-I in NB, resulting in the enhanced cytotoxicity of tumor-specific T cells, and it also increased the expression of MICA/MICB, augmenting NK recognition of tumor cells as well [196].